Incannex Commences Screening in Phase 2 DReAMzz Study of IHL-42X for OSA

Incannex commenced participant screening in its DReAMzz Phase 2 dose confirmation study of IHL-42X, advancing the program toward Phase III.

Key Highlights:

• First clinical sites approved and actively screening potential participants, marking transition to active recruitment.
• IHL-42X holds FDA Fast Track designation, supporting more frequent FDA interactions and a potentially expedited path.
• Study designed to optimize dosing and evaluate objective sleep metrics and patient-reported outcomes for regulatory support.
• Builds on prior Phase 2 results showing up to 83% reduction in AHI and significant patient-reported outcome improvements.
• Company completed CRO appointment, manufacturing, permits, and distribution infrastructure to support the study.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.